- Global Pharma News & Resources
09-Nov-2022 - 11-Nov-2022

6th Antifibrotic Drug Development Summit (AFDD)

  • Location:
    • Crowne Plaza Boston - Woburn, an IHG Hotel
    • Middlesex Canal Park Rd
    • Middlesex County
    • 01801
    • United States
  • View on a map

Returning for the 6th year, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF, NASH, CKD and more in one place at one time, so you can advance the progress of your antifibrotic therapies.

From exploring cellular mechanisms to identify a common fibrotic pathway to bridging the translational gap to prove early therapeutic effectiveness; this unique cross-organ, cross-disease, cross-discipline discussion forum is here to transform your fibrosis research.

Join 100+ industry super giants from Boehringer Ingelheim, Genentech, Gilead, Pfizer, Novartis, and many more in Boston to harness the knowledge you need for your 2022/23 antifibrotic research and drug development.


Industry - Conference + Workshop Day (Earlybird rates available): USD 3946.00,
Industry - Conference Only (Earlybird rates available): USD 2599.00,
Academics - Conference + Workshop Day (Earlybird rates available): USD 3246.00,
Academics - Conference Only (Earlybird rates available): USD 2199.00,
Solution Providers - Conference + Workshop Day (Earlybird rates available): USD 5696.00,
Solution Providers - Conference Only (Earlybird rates available): USD 3599.00

Speakers: Adi Mor Chief Scientific Officer Chemomab, Akshay Krishnamurty Senior Scientist, Cancer Immunology Genentech, Andrew Leask Professor University of Saskatchewan, Andrzej Krolewski Senior Investigator Joslin Diabetes Centre, Anissa Kalinowski Chief Executive Officer Halo Biosciences, Anjali Pandey Senior Vice President Nonclinical R&D and Chemistry ARIA Pharmaceuticals, Anna Zargoska Senior Research Scientist II Gilead, Cheryl Nickerson-Nutter Vice President Research and Development Three Lakes Partners, Christian Hesslinger Senior Expert Translational Medicine and Biomarker Boehringer Ingelheim, Christina Wenglen Head of Research Anamar, David Lagares Director and Head of Matrix and Mechanobiology Program Massachusetts General Hospital, Elizabeth Redente Associate Professor National Jewish Health, Eric White Senior Clinical Program Lead Boehringer Ingelheim, Geoffrey Teixeira Head of Fibrosis Alentis Therapeutics, Haig Aghajanian Co-Founder and Vice President - Research Capstan Therapeutics, Harry Karmouty-Quintana Associate Professor University of Texas, Herman Steen Co-Founder and Chief Executive Officer BiOrion Technologies, Hind Lal Associate Professor University of Alabama at Birmingham, Ilya Korsunsky Instructor of Medicine Harvard Medical School, Jeff Biernaskie Professor University of Calgary, Jeremy O'Connell Chief Scientific Officer and Co-Founder Juvena Therapeutics, Ken Dower Senior Principal Scientist and Associate Fellow - Research Pfizer, Kevin Wei Assistant Professor Harvard University, Lee Borthwick Chief Operating Officer FibroFind, Lindsay McDonald Assistant Professor Medical University of South Carolina, Michael Underhill Professor University of British Columbia, Morten Karsdal Chief Executive Officer Nordic Bioscience, Peter Bunyard Head of Fibrosis Biology RedX Pharma, Philipp Tropberger Senior Principal Scientist Novartis, Richard Stratton Consultant and Senior Lecturer University College London, Rohan Manohar Associate Director - Discovery Biology Scholar Rock, Ryan Feaver Executive Director and Head of Exploratory Biology HemoShear, Shannon Turley Vice President, Immunology and OMNI Biomarker Discovery Genentech, Thomas Fabre Senior Scientist Pfizer, Will Richardson Assistant Professor of Bioengineering University of Arizona